Search - tctmd.com

Displaying 281 - 300 of 363

Sort: Relevancy | Date

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

Yael L. Maxwell

February 14, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

L.A. McKeown

January 30, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Shelley Wood

September 28, 2016

News Daily News

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Shelley Wood

September 28, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Todd Neale

August 04, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

Advertisement

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content